These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12393712)

  • 1. Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells.
    Pisano C; Kollar P; Gianní M; Kalac Y; Giordano V; Ferrara FF; Tancredi R; Devoto A; Rinaldi A; Rambaldi A; Penco S; Marzi M; Moretti G; Vesci L; Tinti O; Carminati P; Terao M; Garattini E
    Blood; 2002 Nov; 100(10):3719-30. PubMed ID: 12393712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase IV inhibition by piclamilast potentiates the cytodifferentiating action of retinoids in myeloid leukemia cells. Cross-talk between the cAMP and the retinoic acid signaling pathways.
    Parrella E; Gianni' M; Cecconi V; Nigro E; Barzago MM; Rambaldi A; Rochette-Egly C; Terao M; Garattini E
    J Biol Chem; 2004 Oct; 279(40):42026-40. PubMed ID: 15292163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro.
    Shiohara M; Dawson MI; Hobbs PD; Sawai N; Higuchi T; Koike K; Komiyama A; Koeffler HP
    Blood; 1999 Mar; 93(6):2057-66. PubMed ID: 10068679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of novel retinoid X receptor-selective ligands on myeloid leukemia differentiation and proliferation in vitro.
    Kizaki M; Dawson MI; Heyman R; Elster E; Morosetti R; Pakkala S; Chen DL; Ueno H; Chao W; Morikawa M; Ikeda Y; Heber D; Pfahl M; Koeffler HP
    Blood; 1996 Mar; 87(5):1977-84. PubMed ID: 8634447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha.
    Gianni' M; Kalaç Y; Ponzanelli I; Rambaldi A; Terao M; Garattini E
    Blood; 2001 May; 97(10):3234-43. PubMed ID: 11342454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
    Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
    Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocytic differentiation of human NB4 promyelocytic leukemia cells induced by all-trans retinoic acid metabolites.
    Idres N; Benoît G; Flexor MA; Lanotte M; Chabot GG
    Cancer Res; 2001 Jan; 61(2):700-5. PubMed ID: 11212271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of retinoic acid receptor-alpha by granulocyte macrophage colony-stimulating factor in human myeloid leukemia cell lines.
    Shimizu T; Takeda K
    Cancer Res; 2000 Aug; 60(16):4544-9. PubMed ID: 10969805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RARα2 and PML-RAR similarities in the control of basal and retinoic acid induced myeloid maturation of acute myeloid leukemia cells.
    Gianni M; Fratelli M; Bolis M; Kurosaki M; Zanetti A; Paroni G; Rambaldi A; Borleri G; Rochette-Egly C; Terao M; Garattini E
    Oncotarget; 2017 Jun; 8(23):37041-37060. PubMed ID: 27419624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia.
    Niitsu N; Higashihara M; Honma Y
    Exp Hematol; 2002 Nov; 30(11):1273-82. PubMed ID: 12423680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways.
    Glasow A; Prodromou N; Xu K; von Lindern M; Zelent A
    Blood; 2005 Jan; 105(1):341-9. PubMed ID: 15339853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death.
    Pendino F; Dudognon C; Delhommeau F; Sahraoui T; Flexor M; Bennaceur-Griscelli A; Lanotte M; Ségal-Bendirdjian E
    Oncogene; 2003 Dec; 22(57):9142-50. PubMed ID: 14668795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia.
    Wang H; Zheng X; Behm FG; Ratnam M
    Blood; 2000 Nov; 96(10):3529-36. PubMed ID: 11071651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A functionally active RARalpha nuclear receptor is expressed in retinoic acid non responsive early myeloblastic cell lines.
    Grande A; Montanari M; Manfredini R; Tagliafico E; Zanocco-Marani T; Trevisan F; Ligabue G; Siena M; Ferrari S; Ferrari S
    Cell Death Differ; 2001 Jan; 8(1):70-82. PubMed ID: 11313705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells.
    Ikezoe T; Tanosaki S; Krug U; Liu B; Cohen P; Taguchi H; Koeffler HP
    Blood; 2004 Jul; 104(1):237-42. PubMed ID: 15026318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells.
    Gu ZM; Wu YL; Zhou MY; Liu CX; Xu HZ; Yan H; Zhao Y; Huang Y; Sun HD; Chen GQ
    Blood; 2010 Dec; 116(24):5289-97. PubMed ID: 20739655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis.
    Ying M; Zhou X; Zhong L; Lin N; Jing H; Luo P; Yang X; Song H; Yang B; He Q
    Mol Cancer Ther; 2013 Feb; 12(2):195-206. PubMed ID: 23243061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells.
    Gianni M; Peviani M; Bruck N; Rambaldi A; Borleri G; Terao M; Kurosaki M; Paroni G; Rochette-Egly C; Garattini E
    Leukemia; 2012 Aug; 26(8):1850-61. PubMed ID: 22354283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid induction of cAMP/PKA pathway during retinoic acid-induced acute promyelocytic leukemia cell differentiation.
    Zhao Q; Tao J; Zhu Q; Jia PM; Dou AX; Li X; Cheng F; Waxman S; Chen GQ; Chen SJ; Lanotte M; Chen Z; Tong JH
    Leukemia; 2004 Feb; 18(2):285-92. PubMed ID: 14628075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.